# ARK Genomic Revolution ETF (0CQL)

**Source:** https://fundology.uk/fund/0cql · ISIN US00214Q3020 · Data: TradingView (LSE closes and returns, delayed), issuer documents, ONS CPIH, FCA FIRDS

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 05/10/2026, 0CQL (ARK Genomic Revolution ETF, ISIN US00214Q3020) closed at $54.60 on the London Stock Exchange. Its ongoing charge is 0.75% a year (about £75 on £10,000). Over the five years to 05/10/2026 its total return was −25.3%, or −41.6% after UK CPIH inflation.

## Summary

ARK Genomic Revolution ETF is an exchange-traded fund (ETF) from ARK, launched in 2014. It tracks the No Underlying Index. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.75% a year — about £75 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is paid out to holders as cash, usually a few times a year.

> This fund is domiciled outside the UK and EU and does not publish the key information document UK rules require, so most UK platforms do not offer it to retail investors. It is shown for reference.

Latest close: **$54.60** (05/10/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | 0CQL |
| ISIN | US00214Q3020 |
| Category | Healthcare |
| Type | ETF |
| Provider | ARK |
| Income | Distributing |
| Ongoing charge | 0.75% a year (£75 per £10,000) |
| Fund size | £1.3bn |
| Launched | 2014 |
| Domicile | United States |

## Past returns (periods to 05/10/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after ONS CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +84.08% | +78.30% | income reinvested |
| 3 years | +88.92% | +70.47% | income reinvested |
| 5 years | -25.30% | -41.60% | income reinvested |

Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published.

## Calendar-year returns

Calendar-year returns of ARK Genomic Revolution ETF in pounds (price only, income paid out not included): 2021 −39.1%, 2022 −50.3%, 2023 +12.2%, 2024 −25.4%, 2025 +15.8%; 2026 to 05/10/2026 +85.5%. Returns of ARK Genomic Revolution ETF in pounds (price only, income paid out not included) over the 12 months to 30/09/2026: +107.4%; to 30/09/2025: +3.5%; to 30/09/2024: −14.8%; to 30/09/2023: −26.2%; to 30/09/2022: −47.1%.

| Year | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 2021 | -39.1% | -41.9% | Price |
| 2022 | -50.3% | -54.5% | Price |
| 2023 | +12.2% | +7.7% | Price |
| 2024 | -25.4% | -28.0% | Price |
| 2025 | +15.8% | +11.8% | Price |
| 2026 to 05/10/2026 | +85.5% | +80.3% | Price |

## Risk metrics

| Window | Volatility | Max drawdown |
|---|---|---|
| 1 year | 41.71% | -20.43% |
| 3 years | 41.35% | -44.83% |
| 5 years | 41.40% | -75.62% |

## Largest fall

Volatility of ARK Genomic Revolution ETF in pounds, annualised from weekly returns to 05/10/2026: 41.7% over 1 year, 41.4% over 3 years, 41.4% over 5 years. Largest fall in the price of ARK Genomic Revolution ETF since October 2021, in pounds: −75.6% from 05/11/2021 to 04/04/2025. The lowest 12-month return of ARK Genomic Revolution ETF in pounds (price only, income paid out not included) since December 2020 was −61.5% (12 months to 17/06/2022); the highest was +101.2% (12 months to 25/09/2026). On 05/10/2026 the price of ARK Genomic Revolution ETF was 29.6% below its highest weekly close since October 2021 (05/11/2021), in pounds.

## Charges compared with similar funds

Ongoing charge of ARK Genomic Revolution ETF 0.75% a year, as of 06/10/2026: 1 of the 18 other healthcare funds charge more, 0 the same and 17 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.75%** per year
- ISA eligible: no
- SIPP eligible: no

## Questions people ask

**What is the ongoing charge of 0CQL?**

The ongoing charge of 0CQL is 0.75% a year — about £75 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of ARK Genomic Revolution ETF 0.75% a year, as of 06/10/2026: 1 of the 18 other healthcare funds charge more, 0 the same and 17 less (share classes counted once).

**Is 0CQL accumulating or distributing?**

0CQL is distributing: income is paid out to holders as cash, usually a few times a year. It pays out annual.

**What is the ISIN of 0CQL?**

The ISIN of 0CQL is US00214Q3020. An ISIN identifies one exact share class of a fund; 0CQL is its ticker on the London Stock Exchange.

**What were 0CQL’s returns in each of the last five years?**

Calendar-year returns of 0CQL in pounds (price only, income paid out not included): 2021 −39.1%, 2022 −50.3%, 2023 +12.2%, 2024 −25.4%, 2025 +15.8%; 2026 to 05/10/2026 +85.5%. Past performance is not a guide to future returns.

**How has 0CQL done after inflation?**

Over the five years to 05/10/2026 0CQL’s total return was −25.3%, or −41.6% after UK CPIH inflation. Past performance is not a guide to future returns.

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.